Advanced Science,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 24, 2024
Abstract
Paclitaxel
(PTX)
is
a
first‐line
chemotherapeutic
drug
for
non‐small
cell
lung
cancer
(NSCLC)
but
it
can
induce
indoleamine
2,3‐dioxygenase
(IDO)
activation,
which
severely
lowers
down
its
immuno‐chemotherapeutic
effect.
To
address
this
issue,
smart
peptide
hydrogelator
Nap–Phe–Phe–Phe–Lys–Ser–Thr–Gly–Gly–Lys–Ala–Pro–Arg–OH
(
Nap‐T
),
co‐assembles
with
PTX
and
an
IDO
inhibitor
GDC0919
to
form
hydrogel
GP@Gel
Nap‐T,
rationally
designed.
Upon
specific
phosphorylation
by
pyruvate
kinase
M2
(PKM2),
overexpressed
biomarker
of
NSCLC,
gradually
converted
Nap–Phe–Phe–Phe–Lys–Ser–Thr(H
2
PO
3
)–Gly–Gly–Lys–Ala–Pro–Arg–OH
Nap‐Tp
leading
dehydrogelation
sustained
release
within
NSCLC
tissues.
The
released
exerts
chemotherapy
on
cells
as
well
immunogenic
death
induction,
while
promotes
the
effect
through
inhibition.
We
find
that
enhances
infiltration
tumor‐infiltrating
immune
reduces
number
immunosuppressive
in
either
tumor
tissues
or
tumor‐draining
lymph
nodes,
thus
enhancing
immuno‐chemotherapy
toward
NSCLC.
With
PKM2‐responsive
strategy,
platform
might
be
applied
treatment
clinic
near
future.
Molecular Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 17, 2025
Malignant
tumors
pose
a
considerable
threat
to
human
life
and
health.
Traditional
treatments,
such
as
radiotherapy
chemotherapy,
often
lack
specificity,
leading
collateral
damage
normal
tissues.
Tumor
microenvironment
(TME)
is
characterized
by
hypoxia,
acidity,
redox
imbalances,
elevated
ATP
levels
factors
that
collectively
promote
tumor
growth
metastasis.
This
review
provides
comprehensive
overview
of
the
nanoparticles
developed
in
recent
years
for
TME-responsive
strategies
or
TME-modulating
methods
therapy.
The
focus
on
designing
synthesizing
can
interact
with
achieve
precisely
controlled
drug
release.
These
activate
release
under
specific
conditions
within
environment,
thereby
enhancing
efficacy
drugs
while
reducing
toxicity
cells.
Moreover,
simply
eliminating
cells
does
not
fundamentally
solve
problem.
Only
comprehensively
regulating
TME
make
it
unsuitable
cell
survival
proliferation
we
more
thorough
therapeutic
effects
reduce
risk
recurrence.
regulation
aim
suppress
metastasis
modulating
various
components
TME.
only
improve
treatment
outcomes
but
also
have
potential
lay
foundation
future
personalized
cancer
therapies.
Journal of the American Chemical Society,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 24, 2025
DNA-mediated
synthetic
cell
communication
enabling
non-natural
signaling
and
regulatory
pathways
is
highly
attractive
but
relies
on
direct
contacts.
Here,
we
report
a
diffusion-based
capable
of
regulating
migration
behaviors
epithelial
adhesion
molecule
(EpCAM)-overexpressed
cancer
cells
in
response
to
apoptosis
events
at
distal
sites.
This
network
enabled
by
multitasking
DNA
nanomachine
that
not
only
mediates
signal
production,
transmission,
regulation
also
amplifies
ligands
situ
specific
receiver
overcome
the
attenuation
during
diffusion.
Leveraging
this
network,
demonstrate
inhibition
migrations
induced
an
anticancer
drug.
Our
system
enriches
current
nanotechnological
tools
for
manipulating
cellular
interactions
function.
It
directs
possible
intervening
strategy
reduce
invasiveness
cells.
Chemistry - A European Journal,
Journal Year:
2024,
Volume and Issue:
30(48)
Published: Aug. 9, 2024
Abstract
Bioinspired
molecular
engineering
strategies
have
emerged
as
powerful
tools
that
significantly
enhance
the
development
of
novel
therapeutics,
improving
efficacy,
specificity,
and
safety
in
disease
treatment.
Recent
advancements
focused
on
identifying
utilizing
disease‐associated
biomarkers
to
optimize
drug
activity
address
challenges
inherent
traditional
such
frequent
administrations,
poor
patient
adherence,
increased
risk
adverse
effects.
In
this
review,
we
provide
a
comprehensive
overview
latest
developments
bioinspired
artificial
systems
(BAS)
use
tailor
therapeutic
responses
drugs
presence
disease‐specific
biomarkers.
We
examine
transition
from
open‐loop
systems,
which
rely
external
cues,
closed‐loop
feedback
capable
autonomous
self‐regulation
response
detail
various
BAS
modalities
designed
achieve
biomarker‐driven
therapy,
including
activatable
prodrug
molecules,
smart
delivery
platforms,
cells,
synthetic
receptor‐based
cell
therapies,
elucidating
their
operational
principles
practical
vivo
applications.
Finally,
discuss
current
future
perspectives
advancement
BAS‐enabled
technology
envision
ongoing
toward
more
programmable
customizable
BAS‐based
therapeutics
will
precision
medicine.
Nanoscale,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 2, 2024
IR780-SLN@O–P
nanoparticles,
delivered
to
the
tumor
site
by
platelet
“backpacking”,
subsequently
act
in
concert
with
photothermal
therapy
and
immunotherapy
effectively
suppress
growth.
Small,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 5, 2024
Abstract
Clinical
evidence
has
demonstrated
that
combining
immune
checkpoint
blockade
(ICB)
therapy
with
chemotherapy
significantly
improves
response
rates
to
ICB
and
therapeutic
efficacy
in
various
tumor
types.
However,
a
convenient
method
for
achieving
synergistic
precise
co‐delivery
of
both
agents
is
still
highly
desirable.
In
this
study,
strategy
co‐delivering
small
interfering
RNA
(siRNA)
encapsulated
vesicle‐like
nanoparticles
(VNP
siRNA
)
chemotherapeutic
drugs
aimed
develop.
It
discovered
the
hydrophilic
drug
mitoxantrone
hydrochloride
(MTO·2HCl)
can
be
captured
into
VNP
.
The
resulting
Cp
MTO
simultaneously
block
checkpoints
via
silencing
induce
effects
on
cells.
mechanism
MTO·2HCl
elucidates,
captures,
demonstrates
superior
effect
through
chemo‐immunotherapy.
This
also
extended
deliver
other
anticancer
drugs,
such
as
doxorubicin
(DOX·HCl),
combination
therapy.
study
provides
facile
enhancing
combined
offering
promising
approach
cancer
treatment.
